Published in final edited form as:

ACS Comb Sci. 2013 July 8; 15(7): 379–386. doi:10.1021/co400055b.

Multicomponent Assembly Processes for the Synthesis of Diverse *Yohimbine* and *Corynanthe* Alkaloid Analogs

Brett A. Granger, Zhiqian Wang, Kyosuke Kaneda, Zhenglai Fang, and Stephen F. Martin*

Department of Chemistry and Biochemistry, The Texas Institute for Drug and Diagnostic Development, The University of Texas at Austin, Austin, Texas 78712, USA

Abstract

A strategy involving a Mannich-type multicomponent assembly process followed by a 1,3-dipolar cycloaddition has been developed for the rapid and efficient construction of parent heterocyclic scaffolds bearing indole and isoxazolidine rings. These key intermediates were then readily elaborated using well-established protocols for refunctionalization and cross-coupling to access a diverse 180-member library of novel pentacyclic and tetracyclic compounds related to the *Yohimbine* and *Corynanthe* alkaloids. Several other new multicomponent assembly processes were developed to access dihydro- β -carboline-fused benzodiazepines, pyrimidinediones, and rutaecarpine derivatives.

Keywords

Combinatorial chemistry; dipolar cycloaddition; heterocycle; Mannich; multicomponent reaction

INTRODUCTION

The discovery of small molecules that potently and selectively modulate biological targets is a critical endeavor that enables fundamental studies of complex systems using temporal biological probes and that generates potential drug leads to treat medical abnormalities. Once a promising lead compound is identified, its physiochemical properties may be fine-tuned through selective modification of functional groups and substituents. In this context, others have developed useful strategies for the preparation of small molecule libraries toward the goal of identifying compounds that display potent activity toward known targets via high throughput screening (HTS).¹

The *Yohimbine* and *Corynanthe* alkaloids, of which yohimbine (**1**), tetrahydroalstonine (**2**), and geissoschizine (**3**) are typical members (Figure 1), are well documented to elicit a wide array of useful biological effects.² Accordingly, analogs of these compounds are attractive targets for creating unique libraries for HTS. The related octahydroindolo[2,3-*a*]quinolizine-2-amine scaffold (**4**) is also present in compounds that exhibit various important biological activities as exemplified by compounds such as the derived amide **5** and the sulfonamide **6**, both of which are potent α_2 -adrenoceptor antagonists.³

sfmartin@mail.utexas.edu.

SUPPORTING INFORMATION

Experimental procedures, spectral data for all new compounds, full characterization data for representative compounds, LCMS data for representative compounds, and tabulated physiochemical properties for representative compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

During the course of developing concise syntheses of **2** and **3**,⁴ we discovered a novel Mannich-type multicomponent assembly process (MCAP) that inspired the subsequent development of a number of three- and four-component MCAPs that generate highly functionalized intermediates. The combination of these MCAPs in tandem with various ring closing reactions that are enabled by selective pairing of resident functional groups has led to a powerful strategy for the diversity oriented synthesis (DOS) of a broad array of unique heterocycles⁵ comprising the benzodiazepine,⁶ benzoxazocine,⁷ benzazocine, isoindolinone,⁸ tetrahydrobenzonaphtheridine, pyridazine, norbenzomorphan, 2-aryl piperidine, and tetrahydroisoquinoline scaffolds.^{9,10} More recently we reported a useful extension of this general approach to DOS for the facile synthesis of compounds containing the octahydroindolo[2,3-*a*]quinolizine-2-amine scaffold.¹¹ We herein report the application of this strategy to the rapid synthesis of a 180-member library of these compounds, many of which possess substitution patterns that were heretofore unknown.

RESULTS AND DISCUSSION

In close analogy with our syntheses of **2** and **3**,⁴ the first step toward creating a novel library of compounds possessing the yohimboid and corynantheoid skeletons involved the reaction of the readily available dihydro- β -carbolines **7–9**¹² with *trans*-crotonyl chloride and silyl enol ether **10**¹³ to form the aldehydes **11–13** (Scheme 1). When compounds **11–13** were condensed with *N*-methylhydroxylamine in toluene, the intermediate nitrone that was formed underwent an intramolecular 1,3-dipolar cycloaddition with the crotonamide moiety to furnish isoxazolidines **14–16** in 43–60% yield over the two steps. The relative stereochemistry resident in **14–16** was confirmed by single crystal X-ray analysis of a compound derived from **16** (*vide infra*). Reduction of the lactam moiety in **14** with lithium aluminum hydride provided amine **17** in 98% yield.

Having prepared the nor-bromo scaffolds **14** and **17**, we envisioned that *N,O*-bond cleavage followed by nitrogen functionalization would lead to the generation of an initial collection of small molecules (Scheme 2). In the event, reaction of isoxazolidines **14** and **17** with nickel boride in methanol¹⁴ delivered amines **18** and **19** in 68% and 64% yields, respectively. The secondary amine functionality resident in **18** and **19** was an obvious point for diversification, and the reaction of these intermediates with a series of *N*-functionalizing reagents **20** under standard conditions gave chemsets **21** and **22** (Figure 2, Table 1). A wide array of *N*-functionalizing reagents was selected that included alkyl, aryl, and heteroaryl acid chlorides, sulfonyl chlorides, isocyanates, isothiocyanates, aldehydes and chloroformates with varying electronic properties to generate a set of compounds that would enable an exploration of structure-activity relationships (SAR) for any actives that were identified during screening. Notably, these transformations were highly selective for reaction at the amino group. On the rare occasions that the undesired *O*-functionalized products were detected, they were formed in only trace quantities. When **18** and **19** were treated with aldehydes, the initially-formed cyclic *N,O*-acetals, which were sufficiently stable for isolation, underwent reduction by the action of sodium cyanoborohydride in refluxing acetonitrile to furnish *N*-alkylated amino derivatives.

The aryl bromide moiety in the halogenated scaffolds **15** and **16** could be exploited in Suzuki¹⁵ cross-coupling reactions, allowing for the creation of novel products possessing substitution patterns at the 5- and 8-positions that were not otherwise accessible. Accordingly, coupling of **15** with boronic acids **23** provided biaryl chemset **24** (Scheme 3, Figure 3, Table 2). In order to generate compounds that could be used to explore SAR, electron neutral **23**{*1–3*}, electron deficient **23**{*4–10*}, and electron rich **23**{*11–14*} boronic acids with varying substitution patterns were used as inputs.

Scission of the *N,O*-bond in **24**{1} and **24**{5}, followed by reaction of the intermediate amino alcohol moiety with *N*-functionalizing agents **20** led to the formation of chemset **26** (Scheme 4, Figure 2, Table 3). In analogous fashion, chemset **29** was prepared after reduction of the lactam moiety of **24**{1} and **24**{13} with the complex of alane with *N,N*-dimethylethylamine.

The 8-bromo scaffold **16** was also readily diversified via Suzuki reactions to provide chemset **30** (Scheme 5, Figure 3, Table 4). We determined the structure for compound **30**{12} by X-ray crystallography, thereby confirming our initial assignment of relative stereochemistry.

Nickel boride mediated *N,O*-bond cleavage of **30**{1}, **30**{3}, and **30**{14} provided the corresponding amino alcohols, which were subjected to *N*-functionalization by reagents **20** to afford chemset **32** (Scheme 6, Figure 2, Table 5). After reduction of lactams **30** with lithium aluminum hydride, analogous chemistry allowed for the preparation of chemset **35** from amines **33**.

We have previously reported the development of several novel MCAPs for the synthesis of fused-tetrahydroisoquinoline scaffolds,⁹ and it occurred to us that we might apply this chemistry to the synthesis of unique scaffolds derived from **9**. Compounds containing the pyrimidinedione ring exemplified in **39** are known to exhibit hypotensive, diuretic, and anti-anoxic effects.¹⁶ In initial experiments toward accessing this heterocyclic systems, **9** was allowed to react with the silyl ketene acetal **36**¹⁷ in the presence of a sub-stoichiometric amount of TMSOTf. The putative intermediate amino ester **37** was then treated with phenylisocyanate to give the pyrimidinedione **39**, presumably by cyclization of **38** (Scheme 7).^{9a} However, when we recently returned to this reaction to prepare a compound library derived from this scaffold, only small amounts of **39** were isolated, and varying amounts of the amino ester and urea ester derived from protodesilylation of **37** and **38**, respectively, were observed instead. After some experimentation, we found that adding TBAF to the reaction mixture was necessary to effect complete cyclization, and **39** was then reproducibly obtained in 45% overall yield from **9**. This useful procedure provides convenient access to pyrimidinediones from **9** in one-pot procedure that represents a marked improvement upon known methods to such compounds.¹⁸

The quinazolinocarboline alkaloid rutaecarpine (**41**) was isolated from *Evodia Rutaecarpa* in 1915,¹⁹ and this compound together with a number of its derivatives displays a wide array of biological activities.²⁰ We thus envisioned that compounds related to **41** having substituents on the indole ring might be attractive compounds for screening. In previous work, we discovered that reaction of the hydrochloride salt of **7** with *o*-azidobenzoyl chloride (**40**) provided a novel entry to **41**,^{9a} so we queried whether this chemistry might also be applied to bromo-substituted analogs of **41**. In order to establish the underlying feasibility of this approach to rutaecarpine derivatives, imine **9** and *o*-azidobenzoyl chloride (**40**) were heated in refluxing 1,2-dichloroethane to furnish **42**, which is known as a selective COX-2 inhibitor,²¹ in 63% yield. Derivatives prepared from **42** via cross-coupling chemistry may exhibit novel biological activities.

The 1,5-benzodiazepin-2-one scaffold present in **43** is found in compounds that bind to various targets including the interleukin-1 β converting enzyme (ICE)²² and voltage-gated potassium channels.²³ Moreover, triazolo-fused benzodiazepine scaffolds are present in compounds that have been reported to inhibit serine protease²⁴ and to bind to the benzodiazepine receptor.²⁵ We thus decided to fuse this scaffold to the 8-bromo-3,4-dihydro- β -carboline scaffold (**9**) to provide a novel set of compounds that might be screened. In the event, sequential treatment of **9** with TMSOTf, ethynylmagnesium bromide, and the

acid chloride **40** afforded an intermediate amide that underwent cyclization via an intramolecular 1,3-dipolar cycloaddition upon warming to room temperature to generate the novel benzodiazepine **43** in 63% yield. Further elaboration of **43** by cross-coupling reactions may also be readily envisioned.

BIOLOGICAL ACTIVITY

High throughput biological screening of the 180-member library of *Yohimbine* and *Corynanthe* alkaloid analogs through the NIH Molecular Library Probe Production Center Network (MLPCN) and the National Institute of Mental Health's (NIMH) Psychoactive Drug Screening Program (PDSP) is currently underway in hopes of identifying compounds with useful biological activities for further development. Notably, compound **17** was found to promote the differentiation of acute myeloid leukemia cells,²⁶ and is an agonist of mouse serotonin receptor 2A,²⁷ which may have implications in the treatment of schizophrenia, depression, and drug addiction.^{28–30} Additionally compound **32**{1,22} is a human trace amine associated receptor 1 (hTAAR1) antagonist.³¹

SUMMARY

We have prepared a 180-member library of *Yohimbine* and *Corynanthe* alkaloid analogs utilizing a general sequence that features an MCAP followed by a 1,3-dipolar cycloaddition to generate functionalized scaffolds that were readily diversified using several well established reactions for refunctionalization and cross-coupling. An improved procedure for the generation of pyrimidinediones was developed, along with methods for formation of benzodiazepines and rutaecarpine derivatives. These compounds have been submitted to the NIH Molecular Libraries Small Molecule Repository (MLSMR) for distribution to HTS centers within the Molecular Libraries Probe Production Centers Network (MLPCN) and biological screening is currently underway. Further applications of novel MCAPs are in progress, and the results of these investigations will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the National Institutes of Health (GM 86192 and GM 24539) and the Robert A. Welch Foundation (F-0652) for their generous support of this work. We also thank Dr. Karin Keller (The University of Texas at Austin) for her assistance with LCMS experiments and Dr. Vincent Lynch (The University of Texas at Austin) for performing X-ray crystallography.

References

1. (a) Brenner S, Lerner RA. Encoded Combinatorial Chemistry. *Proc Natl Acad Sci USA*. 1992; 89:5381–5383. [PubMed: 1608946] (b) Njardarson JT, Gaul C, Shan D, Huang X-Y, Danishefsky SJ. Discovery of Potent Cell Migration Inhibitors through Total Synthesis: Lessons from Structure-Activity Studies of (+)-Migrastatin. *J Am Chem Soc*. 2004; 126:1038–1040. [PubMed: 14746469] (c) Kaiser M, Wetzel S, Kumar K, Waldmann H. Biology-Inspired Synthesis of Compound Libraries. *Cell Mol Life Sci*. 2008; 65:1186–1201. [PubMed: 18193390] (d) Schreiber SL. Target-Oriented and Diversity-Oriented Organic Synthesis in Drug Discovery. *Science*. 2000; 287:1964–1969. [PubMed: 10720315]
2. For general reviews of the structure, bioactivity, and synthesis of indole alkaloids of the *Yohimbine* and *Corynanthe* groups, see: Brown RT, Saxton JE. *Indoles*. Wiley-InterscienceNew York1983Szántay C, Blaskó C, Honty K, Dörnyei G, Brossi A. *The Alkaloids, Chemistry and*

Physiology. Academic Press New York 1986 Lounasmaa M, Tolvanen A, Saxton JE. Monoterpenoid Indole Alkaloids. Wiley-Interscience New York 1994

3. (a) Klioze SS, Ehrigott FJ Jr, Wilker JC, Woodward DL, Repke DB. Synthesis and Antihypertensive Activity of 2-Benzamido-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizines. *J Med Chem.* 1979; 22:1497–1504. [PubMed: 536994] (b) Clark RD, Repke DB, Berger J, Nelson JT, Kilpatrick AT, Brown CM, MacKinnon AC, Clague RU, Spedding M. Structure-Affinity Relationships of 12-Sulfonyl Derivatives of 5,8,8a,9,10,11,12,12a,12,13a-Decahydro-6H-isoquino[2,1-g][1,6]naphthyridines at α -Adrenoceptors. *J Med Chem.* 1991; 34:705–717. [PubMed: 1671705] (c) Clark RD, Nelson JT, Repke DB. Stereospecific Synthesis of the (3a α , 11 α , 12a α)-decahydrobenzo[a]pyrrolo[3,2-g]quinolizine ring system. *J Heterocyclic Chem.* 1993; 30:829–831.
4. Martin SF, Benage B, Hunter JE. A Concise Strategy for the Syntheses of Indole Alkaloids of the Heteroyohimbold and Corynantheoid Families. Total Syntheses of ($\pm$)-Tetrahydroalstonine, ($\pm$)-Cathenamine and ($\pm$)-Geissoschizine. *J Am Chem Soc.* 1988; 110:5925–5927.
5. (a) Sunderhaus JD, Dockendorff C, Martin SF. Applications of Multicomponent Reactions for the Synthesis of Diverse Heterocyclic Scaffolds. *Org Lett.* 2007; 9:4223–4226. [PubMed: 17887692] (b) Sunderhaus JD, Dockendorff C, Martin SF. Synthesis of Diverse Heterocyclic Scaffolds via Tandem Additions to Imine Derivatives and Ring-forming reactions. *Tetrahedron.* 2009; 65:6454–6469. [PubMed: 20625454] (c) Donald JR, Granger BA, Hardy S, Sahn JJ, Martin SF. Applications of Multicomponent Assembly Processes to the Facile Synthesis of Diversely Functionalized Nitrogen Heterocycles. *Heterocycles.* 2012; 84:1089–1112. [PubMed: 22451742]
6. (a) Donald JR, Martin SF. Synthesis and Diversification of 1,2,3-Triazole-fused 1,4-Benzodiazepine Scaffolds. *Org Lett.* 2011; 13:852–855. [PubMed: 21275426] (b) Donald JR, Wood RR, Martin SF. Application of a Sequential Multicomponent Assembly Process/Huisgen Cycloaddition Strategy to the Preparation of Libraries of 1,2,3-Triazole-fused 1,4-Benzodiazepines. *ACS Combi Sci.* 2012; 14:135–143.
7. Sahn JJ, Martin SF. Facile Syntheses of Substituted, Conformationally-constrained Benzoxazocines and Benzazocines via Sequential Multicomponent Assembly and Cyclization. *Tetrahedron Lett.* 2011; 52:6855–6858. [PubMed: 22711939]
8. (a) Sahn JJ, Su JY, Martin SF. Facile and Unified Approach to Skeletally Diverse, Privileged Scaffolds. *Org Lett.* 2011; 13:2590–2593. [PubMed: 21513290] (b) Sahn JJ, Martin SF. Expedient Synthesis of Norbenzomorphan Library via Multicomponent Assembly Process Coupled with Ring-Closing Reactions. *ACS Combi Sci.* 2012; 14:496–502.
9. (a) Granger BA, Kaneda K, Martin SF. Multicomponent Assembly Strategies for the Synthesis of Diverse Tetrahydroisoquinoline Scaffolds. *Org Lett.* 2011; 13:4542–4545. [PubMed: 21834504] (b) Granger BA, Kaneda K, Martin SF. Libraries of 2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinoline-2-amine Derivatives via a Multicomponent Assembly Process/1,3-Dipolar Cycloaddition Strategy. *ACS Combi Sci.* 2012; 14:75–79.
10. (a) Welsch ME, Snyder SA, Stockwell BR. Privileged Structures for Library Design and Drug Discovery. *Curr Opin Chem Biol.* 2010; 14:347–361. [PubMed: 20303320] (b) Horton DA, Bourne GT, Smythe ML. The Combinatorial Synthesis of Bicyclic Privileged Structures or Privileged Substructures. *Chem Rev.* 2003; 103:893–930. [PubMed: 12630855]
11. Wang Z, Kaneda K, Fang Z, Martin SF. Diversity Oriented Synthesis: Concise Entry to Novel Derivatives of *Yohimbine* and *Corynanthe* Alkaloids. *Tetrahedron Lett.* 2012; 53:477–479. [PubMed: 22544982]
12. Glennon RA, Grella B, Tyacke RJ, Lau A, Westaway J, Hudson AL. Binding of β -Carbolines at Imidazoline I₂ Receptors: A Structure-Affinity Investigation. *Bioorg Med Chem Lett.* 2004; 14:999–1002. [PubMed: 15013009]
13. Jung ME, Blum RB. Generation of the Enolate of Acetaldehyde from Non-carbonyl Substances and its C-alkylation, O-alkylation, and O-silylation. *Tetrahedron Lett.* 1977; 18:3791–3794.
14. Jones AD, Knight DW, Thornton SR. On the Lewis Acid-Induced [1,3]-Dipolar Cycloaddition of Allylic and Homoallylic Alcohols to *N*-Methyl-*C*-phenyl Nitron. *J Chem Soc, Perkin Trans 1.* 1999:3337–3344.
15. Ishiyama T, Murata M, Miyaura N. Palladium(0)-Catalyzed Cross-Coupling Reactions of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters. *J Org Chem.* 1995; 60:7508–7510.

16. (a) Kaneko, H.; Nagatsuka, T. Pyrimido[2,1-a]isoquinoline Derivatives Jpn. Kokai Tokkyo Koho JP 45009467. 1971. (b) Lombardino, JG.; McLaMore, WM.; Laubach, GD. Azabenzopyridocolines. U. S. Patent No. 3,021,331. 1962. (c) DuPont, R.; Lardenois, P.; Morel, C.; Frost, J.; Koletar, GI. Derivatives of Fluorenes and Fluoranthenes and Process for their Preparation. U. S. Patent No. 4,277,476. 1981. (d) Koletar, GI.; Frost, J.; DuPont, R.; Lardenois, P.; Morel, C.; Najer, H. Pyrimid-and Imidazo-pyridoindole Derivatives. U. S. Patent No. 4,358,451. 1982.
17. Slougui N, Rousseau G. On the Ketene Alkylsilyl Acetal Preparations. *Synth Commun.* 1987; 17:1–11.
18. (a) DeStevens G, Lukaszewski H, Sklar M, Halamandaris A, Blattar HM. Investigations in Heterocycles. XI. Tetracyclic and Pentacyclic Indolo[2,3-a]quinolizines. *J Org Chem.* 1962; 27:2457–2462. (b) DeStevens G, Sklar M. Investigations in Heterocycles. XIV. 2- and 3-Azaoctahydroindolo[2,3a]quinolizines. *J Org Chem.* 1963; 28:3210–3212. (c) De la Figuera N, García-López MT, Herranz R, González-Muñiz R. New Scaffolds for Peptidomimetics. Synthetic Approaches towards 2,4-Dioxooctahydropyrimido[1',6':1,2]pyrido[3,4-b]indole-6-carboxylic Acid Derivatives. *Heterocycles.* 1999; 51:265–280.
19. Asahina Y, Kashiwaki K. *J Pharm Soc Jpn.* 1915:1293.
20. For reviews on the biological properties of rutaecarpine and derivatives thereof, see: Sheu J-R. Pharmacological Effects of Rutaecarpine, an Alkaloid Isolated from *Evodia rutaecarpa*. *Cardiovascular Drug Reviews.* 1999; 17:237–245. Lee SH, Son J-K, Jeong BS, Jeong T-C, Chang HW, Lee E-S, Jahng Y. Progress in the Studies on Rutaecarpine. *Molecules.* 2008; 13:272–300. [PubMed: 18305418]
21. Lee ES, Kim SI, Lee SH, Jeong TC, Moon TC, Chang HW, Jahng Y. Synthesis and COX Inhibitory Activities of Rutaecarpine Derivatives. *Bull Korean Chem Soc.* 2005; 26:1975–1980.
22. Batchelor, MJ.; Bebbington, D.; Bemis, GW.; Fridman, WH.; Gillespie, RJ.; Golec, JMC.; Gu, Y.; Lauffer, DJ.; Livingston, DJ.; Matharu, SS.; Mullican, MD.; Murcko, MA.; Murdoch, R.; Nyce, PL.; Robidoux, ALC.; Wannamaker, MW.; Wilson, KY.; Zelle, RE. Preparation of Bicyclic Peptide Derivatives as Interleukin-1 β Converting Enzyme Inhibitors. U. S. Patent No. 3,021,331. 1962.
23. Clareman, DA.; Liverton, N.; Selnick, GG.; Smith, GR. Preparation of Novel *N*-(1-Alkyl-5-phenyl-2,3,4,5-tetrahydro-1*H*-benzo[b][1,4]diazepin-3-yl)acetamides for Treatment of Arrhythmia. U. S. Patent No. 5,726,171. 1998.
24. Mohapatra DK, Maity PK, Shabab M, Khan MI. Click Chemistry based Rapid One-pot Synthesis and Evaluation for Protease Inhibition of New Tetracyclic Triazole Fused Benzodiazepine Derivatives. *Bioorg Med Chem Lett.* 2009; 19:5241–5245. [PubMed: 19648009]
25. Bertelli L, Biagi G, Giorgi I, Livi O, Manera C, Scartoni V, Martini C, Giannaccini G, Trincavelli L, Barili PL. 1,2,3-Triazolo[1,5-a][1,4]- and 1,2,3-Triazolo[1,5-a][1,5]benzodiazepine Derivatives: Synthesis and Benzodiazepine Receptor Binding. *Il Farmaco.* 1998; 53:305–311. [PubMed: 9658589]
26. [accessed 3/11/2013] HTS to identify compounds that promote myeloid differentiation with MLPCN compound set. found at: <http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=624256>
27. [accessed 3/11/2013] Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A). found at: <http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=624169>
28. Raehal KM, Bohn LM. The Role of Beta Arrestin2 in the Severity of Antinociceptive Tolerance and Psychodependence Induced by Different Opioid Pain in Therapeutics. *Neuropharmacology.* 2011; 60:58–65. [PubMed: 20713067]
29. Allen JA, Yadav PN, Roth BL. Insights into the Regulation of 5-HT2A Serotonin Receptors by Scaffolding Proteins and Kinases. *Neuropharmacology.* 2008; 55:961–968. [PubMed: 18640136]
30. Bohn LM, McDonald PH. Seeking Ligand Bias: Assessing GPCR Coupling to Beta-Arrestins for Drug Discovery. *Drug Discov Today Technol.* 2010; 7:e37–e42. [PubMed: 21218149]
31. [accessed on 3/11/2013] Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1). found at: <http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=624466#aDescription>

Figure 1.
Natural products and compounds containing the octahydroindolo[2,3-*a*] quinolizine scaffold

Figure 2.
N-Functionalizing reagents.

Figure 3.
Boronic acids.

Scheme 1.
 Synthesis of isoxazolidine scaffolds **14–17**.

Scheme 2.

N,O-Bond cleavage and *N*-functionalization.

Conditions: (a) **20**{1–11}, Et₃N, CH₂Cl₂; (b) **20**{12–14}, Et₃N, CH₂Cl₂; (c) **20**{15–24}, CH₂Cl₂; (d) **20**{25–28}, CH₂Cl₂; (e) **20**{29–31}, MeCN, 82 °C; then NaBH₃CN, AcOH, rt; (f) **20**{32–33}, Na₂CO₃, THF/H₂O.

Scheme 3.

Preparation of biaryl chemset **24** via Suzuki coupling.

Scheme 4.

Preparation of the 5-substituted library via lactam reduction, *N,O*-bond cleavage, and *N*-functionalization.

Conditions: (a) **20**{1–11}, Et₃N, CH₂Cl₂; (b) **20**{12–14}, Et₃N, CH₂Cl₂; (c) **20**{15–24}, CH₂Cl₂; (d) **20**{25–28}, CH₂Cl₂; (e) **20**{29–31}, MeCN, 82 °C; then NaBH₃CN, AcOH, rt; (f) **20**{32–33}, Na₂CO₃, THF/H₂O.

Scheme 5.

Preparation of biaryl chemset **30** via Suzuki coupling.

Scheme 6.

Preparation of the 8-substituted library via lactam reduction, *N,O*-bond cleavage, and *N*-functionalization.

Conditions: (a) **20**{1–11}, Et₃N, CH₂Cl₂; (b) **20**{12–14}, Et₃N, CH₂Cl₂; (c) **20**{15–24}, CH₂Cl₂; (d) **20**{25–28}, CH₂Cl₂; (e) **20**{29–31}, MeCN, 82 °C; then NaBH₃CN, AcOH, rt; (f) **20**{32–33}, Na₂CO₃, THF/H₂O.

Scheme 7.
Preparation of scaffolds via novel MCAP chemistry.

Table 1Preparation of **21** and **22** via *N*-Functionalization

entry	<i>N</i> -functionalizing reagent	product	yield (%)
1	20 {1}	21 {1}	53
2	20 {3}	21 {3}	89
3	20 {5}	21 {5}	99
4	20 {8}	21 {8}	87
5	20 {12}	21 {12}	57
6	20 {16}	21 {16}	82
7	20 {17}	21 {17}	77
8	20 {18}	21 {18}	85
9	20 {20}	21 {20}	58
10	20 {21}	21 {21}	92
11	20 {23}	21 {23}	75
12	20 {24}	21 {24}	94
13	20 {26}	21 {26}	49
14	20 {32}	21 {32}	89
15	20 {33}	21 {33}	59
16	20 {35}	21 {35}	57
17	20 {36}	21 {36}	64
18	20 {3}	22 {3}	53
19	20 {5}	22 {5}	81
20	20 {10}	22 {10}	83
21	20 {13}	22 {13}	57
22	20 {14}	22 {14}	56
23	20 {15}	22 {15}	98
24	20 {16}	22 {16}	92
25	20 {17}	22 {17}	93
26	20 {18}	22 {18}	91
27	20 {20}	22 {20}	65
28	20 {21}	22 {21}	57
29	20 {22}	22 {22}	60
30	20 {23}	22 {23}	75
31	20 {24}	22 {24}	82
32	20 {26}	22 {26}	89
33	20 {27}	22 {27}	88
34	20 {28}	22 {28}	99
35	20 {29}	22 {29}	90
36	20 {31}	22 {31}	73
37	20 {34}	22 {34}	57
38	20 {35}	22 {35}	81
39	20 {36}	22 {36}	72

Table 2Preparation of chemset **24**.

entry	Boronic acid	product	yield (%)
1	23 {1}	24 {1}	90
2	23 {2}	24 {2}	92
3	23 {3}	24 {3}	71
4	23 {4}	24 {4}	44
5	23 {5}	24 {5}	85
6	23 {6}	24 {6}	66
7	23 {11}	24 {11}	58
8	23 {13}	24 {13}	56
9	23 {14}	24 {14}	91

Table 3Preparation of chemsets **26** and **29**.

entry	Amino alcohol	N-function alizing reagent	Product	Yield (%)
1	25 {1}	20 {2}	26 {1,2}	98
2	25 {1}	20 {3}	26 {1,3}	93
3	25 {1}	20 {4}	26 {1,4}	58
4	25 {1}	20 {13}	26 {1,13}	57
5	25 {1}	20 {17}	26 {1,17}	93
6	25 {1}	20 {18}	26 {1,18}	77
7	25 {1}	20 {26}	26 {1,26}	48
8	25 {1}	20 {30}	26 {1,30}	68
9	25 {1}	20 {36}	26 {1,36}	51
10	25 {5}	20 {1}	26 {5,1}	85
11	25 {5}	20 {15}	26 {5,15}	99
12	25 {5}	20 {25}	26 {5,25}	99
13	25 {5}	20 {35}	26 {5,35}	83
14	28 {1}	20 {2}	29 {1,2}	78
15	28 {1}	20 {3}	29 {1,3}	85
16	28 {1}	20 {10}	29 {1,10}	74
17	28 {1}	20 {18}	29 {1,18}	41
18	28 {1}	20 {30}	29 {1,30}	72
19	28 {14}	20 {3}	29 {14,3}	55
20	28 {14}	20 {15}	29 {14,15}	72

Table 4Preparation of chemset **30**.

entry	Boronic acid	product	yield (%)
1	23 {1}	30 {1}	68
2	23 {2}	30 {2}	99
3	23 {3}	30 {3}	64
4	23 {4}	30 {4}	98
5	23 {5}	30 {5}	81
6	23 {6}	30 {6}	76
7	23 {7}	30 {7}	62
8	23 {8}	30 {8}	77
9	23 {9}	30 {9}	67
10	23 {10}	30 {10}	83
11	23 {12}	30 {12}	98
12	23 {13}	30 {13}	83
13	23 {14}	30 {14}	87

Table 5Preparation of chemsets **32** and **35**.

entry	Amino alcohol	N-function alizing reagent	Product	Yield (%)
1	31 {1}	20 {1}	32 {1,1}	99
2	31 {1}	20 {3}	32 {1,3}	87
3	31 {1}	20 {5}	32 {1,5}	98
4	31 {1}	20 {6}	32 {1,6}	99
5	31 {1}	20 {8}	32 {1,8}	98
6	31 {1}	20 {9}	32 {1,9}	99
7	31 {1}	20 {10}	32 {1,10}	92
8	31 {1}	20 {11}	32 {1,11}	98
9	31 {1}	20 {13}	32 {1,13}	99
10	31 {1}	20 {15}	32 {1,15}	97
11	31 {1}	20 {16}	32 {1,16}	89
12	31 {1}	20 {17}	32 {1,17}	94
13	31 {1}	20 {18}	32 {1,18}	97
14	31 {1}	20 {19}	32 {1,19}	98
15	31 {1}	20 {22}	32 {1,22}	99
16	31 {1}	20 {24}	32 {1,24}	92
17	31 {1}	20 {25}	32 {1,25}	89
18	31 {1}	20 {26}	32 {1,26}	94
19	31 {1}	20 {27}	32 {1,27}	99
20	31 {1}	20 {28}	32 {1,28}	95
21	31 {1}	20 {30}	32 {1,30}	87
22	31 {1}	20 {35}	32 {1,35}	85
23	31 {1}	20 {36}	32 {1,36}	91
24	31 {3}	20 {3}	32 {3,3}	81
25	31 {3}	20 {5}	32 {3,5}	78
26	31 {3}	20 {15}	32 {3,15}	72
27	31 {3}	20 {16}	32 {3,16}	85
28	31 {3}	20 {17}	32 {3,17}	80
29	31 {3}	20 {18}	32 {3,18}	81
30	31 {3}	20 {19}	32 {3,19}	87
31	31 {3}	20 {22}	32 {3,22}	79
32	31 {14}	20 {1}	32 {14,1}	99
33	31 {14}	20 {3}	32 {14,3}	85
34	31 {14}	20 {5}	32 {14,5}	89
35	31 {14}	20 {9}	32 {14,9}	95
36	31 {14}	20 {15}	32 {14,15}	89
37	31 {14}	20 {16}	32 {14,16}	89
38	31 {14}	20 {17}	32 {14,17}	83
39	31 {14}	20 {18}	32 {14,18}	72

entry	Amino alcohol	N-function alizing reagent	Product	Yield (%)
40	31 {14}	20 {19}	32 {14,19}	85
41	31 {14}	20 {26}	32 {14,26}	89
42	31 {14}	20 {35}	32 {14,35}	82
43	31 {14}	20 {36}	32 {14,36}	70
44	34 {1}	20 {3}	35 {1,3}	90
45	34 {1}	20 {5}	35 {1,5}	63
46	34 {1}	20 {17}	35 {1,17}	76
47	34 {1}	20 {18}	35 {1,18}	78
48	34 {1}	20 {26}	35 {1,26}	70
49	34 {1}	20 {27}	35 {1,27}	76
50	34 {1}	20 {28}	35 {1,28}	79
51	34 {1}	20 {30}	35 {1,30}	65
52	34 {3}	20 {2}	35 {3,2}	78
53	34 {3}	20 {3}	35 {3,3}	79
54	34 {3}	20 {5}	35 {3,5}	78
55	34 {3}	20 {6}	35 {3,6}	95
56	34 {3}	20 {7}	35 {3,7}	59
57	34 {3}	20 {9}	35 {3,9}	79
58	34 {3}	20 {15}	35 {3,15}	77
59	34 {3}	20 {17}	35 {3,17}	82
60	34 {3}	20 {18}	35 {3,18}	86
61	34 {3}	20 {19}	35 {3,19}	87
62	34 {3}	20 {26}	35 {3,26}	86
63	34 {3}	20 {27}	35 {3,27}	74
64	34 {3}	20 {28}	35 {3,28}	87
65	34 {3}	20 {35}	35 {3,35}	68
66	34 {3}	20 {36}	35 {3,36}	72
67	34 {14}	20 {3}	35 {14,3}	91
68	34 {14}	20 {5}	35 {14,5}	61
69	34 {14}	20 {6}	35 {14,6}	78
70	34 {14}	20 {9}	35 {14,9}	60
71	34 {14}	20 {17}	35 {14,17}	46
72	34 {14}	20 {18}	35 {14,18}	93
73	34 {14}	20 {19}	35 {14,19}	85
74	34 {14}	20 {26}	35 {14,26}	85
75	34 {14}	20 {27}	35 {14,27}	80